Conditioning with cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia.

abstract：:The preimmune status of the early gestational age fetus provides a permissive environment that bypasses the immunological barrier and permits the engraftment and expression of hemopoietic stem cells (HSC). We used in utero approach to establish long term (greater than 2 years) engraftment and expression of human fetal...

journal_title：Bone marrow transplantation

authors： Zanjani ED,Pallavacini MG,Ascensao JL,Flake AW,Harrison MR,Tavassoli M

更新日期：1992-01-01 00:00:00

abstract：:Infantile osteopetrosis is a lethal disorder resulting from a severe defect in the ability of osteoclasts to resorb bone. The only therapy shown to be capable of providing lasting benefit is allogeneic hematopoietic stem cell transplantation (HCT). We report the outcome of 10 patients with infantile malignant osteopet...

journal_title：Bone marrow transplantation

authors： Eapen M,Davies SM,Ramsay NK,Orchard PJ

更新日期：1998-11-01 00:00:00

abstract：:Acute GVHD (aGVHD) is an immunologic complication of allogeneic hematopoietic cell transplantation (HCT) that can range from mild to life-threatening. Models to predict patients at risk of poor outcomes have been developed using both clinical and laboratory data, and the time to test these models in clinical trials ha...

journal_title：Bone marrow transplantation

authors： Holtan SG,MacMillan ML

更新日期：2016-02-01 00:00:00

abstract：:We examined the effects of bone marrow transplantation (BMT) on immune-mediated inner ear diseases in MRL/Mp-lpr/lpr (MRL/lpr) mice, which manifest not only lupus nephritis but also sensorineural hearing loss (SNHL) at the age of 20 weeks. These mice were treated with cyclophosphamide (CY) and irradiation (5 Gy x 2), ...

journal_title：Bone marrow transplantation

authors： Lee S,Iwai H,Sugiura K,Takeuchi K,Kushida T,Tomoda K,Inaba M,Yamashita T,Ikehara S

更新日期：2000-10-01 00:00:00

abstract：:Four clinical strategies are proposed for the management of CMV disease: prophylaxis, suppression, pre-emptive therapy and treatment. The degree of risk of developing CMV disease and the safety profile of the presently available drugs need to be considered when deciding on the most appropriate approach. We conclude th...

journal_title：Bone marrow transplantation

authors： Prentice HG,Kho P

更新日期：1997-01-01 00:00:00

abstract：:Conditioning regimens preceding hematopoietic SCT (HSCT) usually consist of high-dose chemotherapy. Chemotherapy and radiation therapy are associated with increased formation of free radicals and depletion of critical plasma and tissue antioxidants. Oxidative stress and antioxidant depletion have been described during...

journal_title：Bone marrow transplantation

authors： Sabuncuoğlu S,Kuşkonmaz B,Uckun Çetinkaya D,Ozgüneş H

更新日期：2012-05-01 00:00:00

abstract：:Whereas patients with multiple myeloma continue to relapse after autologous transplantation and are unlikely to be cured, the probability of progression is less after allogeneic transplantation and a proportion of patients may be cured. This is attributable to an immunologically mediated graft-versus-myeloma (GVM) eff...

journal_title：Bone marrow transplantation

authors： Mehta J,Singhal S

更新日期：1998-11-01 00:00:00

abstract：:Reconstitution of the adaptive immune system following allogeneic hematopoietic stem cell transplantation is crucial for beneficial outcome and is affected by several factors, such as GvHD and graft source. The impact of these factors on immune reconstitution has been thoroughly investigated during the early phase aft...

journal_title：Bone marrow transplantation

authors： Gaballa A,Norberg A,Stikvoort A,Mattsson J,Sundberg B,Uzunel M,Remberger M,Uhlin M

更新日期：2018-01-01 00:00:00

abstract：:HLA-G is a non-classical class I molecule which induces tolerance in allogeneic situations by inhibition of cytotoxic NK and CD8 + T cells and by induction of regulatory T cells. Concordantly, in solid organ transplantation HLA-G is associated with a lower risk for acute and chronic rejection, whereas its role in allo...

journal_title：Bone marrow transplantation

authors： Kordelas L,da Silva Nardi F,Wagner B,Ditschkowski M,Liebregts T,Lindemann M,Heinemann FM,Horn PA,Beelen DW,Rebmann V

更新日期：2018-09-01 00:00:00

abstract：:Budesonide (BUD) is a steroid with a low bioavailability, which has been used for the treatment of oral manifestations of chronic GVHD (cGVHD). We retrospectively evaluated the efficacy of BUD in the treatment of gastrointestinal cGVHD. Thirteen patients (median age 47 years) receiving BUD for the treatment of cGVHD a...

journal_title：Bone marrow transplantation

authors： Andree H,Hilgendorf I,Leithaeuser M,Junghanss C,Holzhueter S,Loddenkemper C,Steiner B,Freund M,Wolff D

更新日期：2008-10-01 00:00:00

abstract：:Cyclosporine A (CsA) therapy based on 2-h concentrations (C2) after oral administration has demonstrated low acute rejection rates after solid organ transplantation. We analysed the correlation between C2 and trough (C0) levels of oral CsA therapy in samples obtained twice in consecutive weeks from 58 patients during ...

journal_title：Bone marrow transplantation

authors： Barkholt L,Remberger M,Bodegård H,Ringdén O,Böttiger Y

更新日期：2007-10-01 00:00:00

abstract：:Autologous bone marrow transplantation may contribute to the treatment of several types of lymphoreticular malignancies. Recent studies have suggested that a combination of chemoseparation and immunoseparation may be more effective than either modality alone in eliminating malignant cells from human bone marrow. In th...

journal_title：Bone marrow transplantation

authors： Montgomery RB,Kurtzberg J,Rhinehardt-Clark A,Haleen A,Ramakrishnan S,Olsen GA,Peters WP,Smith CA,Haynes BF,Houston LL

更新日期：1990-06-01 00:00:00

abstract：:We examined whether pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) is capable of improving thrombocytopenia and promoting thrombopoietic reconstitution following lethal irradiation and bone marrow transplantation (BMT) in mice. Immediately after receiving 10 Gy whole body irradia...

journal_title：Bone marrow transplantation

authors： Kabaya K,Shibuya K,Torii Y,Nitta Y,Ida M,Akahori H,Kato T,Kusaka M,Miyazaki H

更新日期：1996-12-01 00:00:00

abstract：:Clostridium difficile is the most common cause of nosocomial diarrhea in the United States and Europe, and is a cause of significant morbidity and mortality among hospitalized patients. A newly identified epidemic strain has been associated with many hospital outbreaks of C. difficile-associated disease (CDAD), raisin...

journal_title：Bone marrow transplantation

authors： Bobak D,Arfons LM,Creger RJ,Lazarus HM

更新日期：2008-12-01 00:00:00

abstract：:Thrombotic microangiopathy (TM) is a serious complication of bone marrow transplantation (BMT) that resembles thrombotic thrombocytopenic purpura (TTP). In attempting to achieve hematopoietic cell chimerism in the pig-to-baboon model, we have observed TM following infusion of high doses (>10(10) cells/kg) of porcine p...

journal_title：Bone marrow transplantation

authors： Bühler L,Goepfert C,Kitamura H,Basker M,Gojo S,Alwayn IP,Chang Q,Down JD,Tsai H,Wise R,Sachs DH,Cooper DK,Robson SC,Sackstein R

更新日期：2001-06-01 00:00:00

abstract：:Severe veno-occlusive (VOD) disease is a major cause of morbidity and mortality in allogeneic bone marrow transplant recipients, and new approaches in managing patients who develop serious VOD is needed. In this report, we describe a patient who underwent transjugular intrahepatic portosystemic stent-shunt (TIPS) for ...

journal_title：Bone marrow transplantation

authors： Lévy V,Azoulay D,Rio B,Vincent F,Rabbat A,Hunault M,Bazarbachi A,Delmer A,Zittoun R

更新日期：1996-08-01 00:00:00

abstract：:We investigated the prognostic relevance of IKZF1 deletions in 118 adult Ph-positive ALL patients who had minimal residual disease (MRD) data under a uniform treatment of allo-SCT following first-line imatinib-based chemotherapy. IKZF1 deletions were identified in 93 patients (78.8%). IKZF1-deleted patients had a lowe...

journal_title：Bone marrow transplantation

authors： Kim M,Park J,Kim DW,Kim YJ,Jeon YW,Yoon JH,Shin SH,Yahng SA,Lee SE,Cho BS,Eom KS,Kim HJ,Min CK,Cho SG,Kim Y,Lee JW,Han K,Min WS,Lee S

更新日期：2015-03-01 00:00:00

abstract：:Infectious complications are frequent events in patients undergoing high-dose cytotoxic chemotherapy with subsequent autologous peripheral blood stem cell transplantation (PBSCT). To evaluate whether a single subcutaneous injection of pegfilgrastim (6 mg) is as safe and effective as daily filgrastim (5 mug/kg/day), 60...

journal_title：Bone marrow transplantation

authors： Staber PB,Holub R,Linkesch W,Schmidt H,Neumeister P

更新日期：2005-05-01 00:00:00

abstract：:The aim of this study was to define factors that significantly influence the early kinetics of donor chimerism after transplantation. In a retrospective study, the percentage of donor chimerism in peripheral blood measured with sex-chromosome-specific probes and fluorescence-in situ hybridization was analyzed in 184 r...

journal_title：Bone marrow transplantation

authors： Mohr B,Koch R,Thiede C,Kroschinsky F,Ehninger G,Bornhäuser M

更新日期：2004-12-01 00:00:00

abstract：:Glucocorticoids for primary therapy of acute GVHD have limited responses. A phase I/II trial tested 4 weeks of deacetylase inhibitor panobinostat started within 48 h of glucocorticoids (1 mg/kg/day prednisone or equivalent) as primary treatment for patients with either classic acute GVHD (n = 16) or acute GVHD overlap...

journal_title：Bone marrow transplantation

authors： Perez L,Fernandez H,Horna P,Riches M,Locke F,Field T,Powers J,Sahakian E,Villagra A,Mishra A,Betts B,Kharfan-Dabaja M,Beato F,Ochoa-Bayona L,Pidala J,Anasetti C

更新日期：2018-11-01 00:00:00

abstract：:The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of 'tumor burden' but also in terms of their underlying biology. High-dose chemotherapy with auto-SCT is one method of reducing the clone size and thereby improving OS. Post-auto-SCT ...

journal_title：Bone marrow transplantation

authors： Dispenzieri A,Seenithamby K,Lacy MQ,Kumar SK,Buadi FK,Hayman SR,Dingli D,Litzow MR,Gastineau DA,Inwards DJ,Micallef IN,Ansell SM,Johnston PB,Porrata LF,Patnaik MM,Hogan WJ,Gertz MA

更新日期：2013-10-01 00:00:00

abstract：:We report the unusual complication of vaginal stenosis occurring after allogeneic bone marrow transplantation (BMT) for leukaemia. This was in all likelihood a manifestation of chronic graft-versus-host disease (cGVHD), although the patient has no other stigmata of this and suffered little acute graft-versus-host dise...

journal_title：Bone marrow transplantation

authors： DeLord C,Treleaven J,Shepherd J,Saso R,Powles RL

更新日期：1999-03-01 00:00:00

abstract：:A double-blind, placebo-controlled study was conducted to evaluate the effect of orally administered pilocarpine on unstimulated whole-saliva flow and composition in 28 patients with chronic graft-versus-host disease (cGVHD). Thirteen patients were treated with pilocarpine of 20 mg/day orally for 7 days, and 15 patien...

journal_title：Bone marrow transplantation

authors： Agha-Hosseini F,Mirzaii-Dizgah I,Ghavamzadeh L,Ghavamzadeh A,Tohidast-Acrad Z

更新日期：2007-04-01 00:00:00

abstract：:The toxicity of the conditioning regimen high-dose busulfan (BU) 16 mg/kg followed by cyclophosphamide (CY) 200 mg/kg has been analysed in 60 adult patients (mean age 36 +/- 9 years) with haematological malignancies, a third of whom had advanced disease, all received the graft from fully HLA-identical siblings. Signif...

journal_title：Bone marrow transplantation

authors： Bandini G,Belardinelli A,Rosti G,Calori E,Motta MR,Rizzi S,Benini C,Tura S

更新日期：1994-05-01 00:00:00

abstract：:Propylene Glycol-Free melphalan HCL for Injection (PGF-Mel) is a new formulation that incorporates Captisol, a specially modified cyclodextrin, to improve melphalan stability. In this phase IIa, open-label, randomized, cross-over design bioequivalence study, the pharmacokinetics of PGF-Mel were compared with the marke...

journal_title：Bone marrow transplantation

authors： Aljitawi OS,Ganguly S,Abhyankar SH,Ferree M,Marks R,Pipkin JD,McGuirk JP

更新日期：2014-08-01 00:00:00

abstract：:Trial outcomes comparing cytokine agents for PBSC mobilization in autologous hematopoietic transplant patients have been controversial. We performed a systematic review and meta-analysis of evidence available on pegfilgrastim vs filgrastim in chemo-cytokine mobilization. Electronic literature searches of PubMed, EMBAS...

journal_title：Bone marrow transplantation

authors： Kim MG,Han N,Lee EK,Kim T

更新日期：2015-04-01 00:00:00

abstract：:Calcineurin inhibitor (CNI)-sparing T-cell depleted (TCD) hematopoietic stem cell transplants (HSCTs) are presumed to be less nephrotoxic than conventional HSCTs. We evaluated incidence and risk factors for kidney failure and chronic kidney disease (CKD) in 231 TCD and 212 conventional HSCT recipients. Kidney failure ...

journal_title：Bone marrow transplantation

authors： Glezerman IG,Devlin S,Maloy M,Bui M,Jaimes EA,Giralt SA,Jakubowski AA

更新日期：2017-05-01 00:00:00

abstract：:High-dose carboplatin, etoposide and ifosfamide (CEI) is an active chemotherapy regimen (HDCT) in solid tumors and lymphomas. In patients with previous exposure to cisplatin, its nephrotoxicity is dose-limiting. To determine the implications of nephrotoxicity on hematological recovery and clinical outcome, we analyzed...

journal_title：Bone marrow transplantation

authors： Beyer J,Rick O,Weinknecht S,Kingreen D,Lenz K,Siegert W

更新日期：1997-11-01 00:00:00

abstract：:The impact of rhinovirus in hematopoietic SCT (HSCT) recipients is not well defined. A retrospective, matched, case-control study of HSCT recipients with rhinovirus was conducted between 2009 and 2011. Controls were matched for timing relative to transplant, malignancy, and stem cell source. There were 47 cases and 94...

journal_title：Bone marrow transplantation

authors： Abandeh FI,Lustberg M,Devine S,Elder P,Andritsos L,Martin SI

更新日期：2013-11-01 00:00:00

abstract：:HLA-haploidentical hematopoietic SCT (HSCT) provides an opportunity for almost all patients who lack HLA-matched sibling donors. The donor availability can be increased by including the collateral related donors (CRDs). We compared clinical outcomes of patients with hematological malignancies, who underwent haploident...

journal_title：Bone marrow transplantation

authors： Zhang YY,Liu DH,Liu KY,Xu LP,Chen H,Han W,Wang Y,Huang XJ

更新日期：2014-04-01 00:00:00